NCT06326034View on ClinicalTrials.gov

Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

January 1, 2023

Study Completion Date

January 1, 2023

Conditions

Diabetic Nephropathy Type 2

Interventions

DRUG

Dapagliflozin

Dapagliflozin 5 mg orally given once daily for four months.

Trial Locations (1)

00964

Mohammed Mahmood Mahmood, Baghdad

All Listed Sponsors

lead

Mohammed Mahmood Mohammed

OTHER